2seventy bio, Inc.
TSVT
$4.99
-$0.01-0.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 84.46% | -72.61% | 12.46% | -75.12% | -70.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.46% | -72.61% | 12.46% | -75.12% | -70.12% |
| Cost of Revenue | -78.21% | -67.82% | -74.97% | -69.82% | -33.24% |
| Gross Profit | 134.41% | 66.64% | 98.75% | 63.10% | -16.41% |
| SG&A Expenses | 17.30% | -47.39% | -0.92% | -49.42% | -38.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.42% | -63.13% | -61.07% | -65.09% | -34.50% |
| Operating Income | 94.94% | 61.43% | 76.53% | 57.54% | 5.78% |
| Income Before Tax | 100.92% | 65.65% | 86.13% | 159.11% | -12.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 100.92% | 65.65% | 86.13% | 159.11% | -12.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.92% | 65.65% | 86.13% | 159.11% | -12.02% |
| EBIT | 94.94% | 61.43% | 76.53% | 57.54% | 5.78% |
| EBITDA | 98.23% | 62.29% | 78.38% | 59.12% | 5.75% |
| EPS Basic | 100.90% | 66.27% | 86.42% | 157.73% | 6.48% |
| Normalized Basic EPS | 101.16% | 66.53% | 81.86% | 61.90% | 19.72% |
| EPS Diluted | 100.90% | 66.27% | 86.42% | 154.22% | 6.48% |
| Normalized Diluted EPS | 101.16% | 66.53% | 81.86% | 63.86% | 19.72% |
| Average Basic Shares Outstanding | 1.89% | 1.85% | 2.12% | 2.39% | 19.79% |
| Average Diluted Shares Outstanding | 2.62% | 1.85% | 2.12% | 7.94% | 19.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |